Pasifolate exatecan is under clinical development by Elucida Oncology and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pasifolate exatecan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pasifolate exatecan overview

Pasifolate exatecan (ELU-001) is under development for the treatment of relapsed and refractory acute myeloid leukemia, colorectal cancer, cholangiocarcinoma, epithelial ovarian cancer, fallopian tube cancer, endometrial cancer, gastric cancer, gastroesophageal junction cancer, hematological malignancies, non-small cell lung cancer, ovarian cancer, platinum resistant, triple negative breast cancer, metastatic brain tumor  (brain metastases) and for other solid tumors. The drug candidate is a small molecule drug conjugate (SMDC) consisting of folate moeity conjugated with topoisomerase 1 inhibitor. It acts by targeting folate receptor. It is being developed based on targeted nanoparticle C’Dot drug conjugate technology. It is administered through intravenous route.

Elucida Oncology overview

Elucida Oncology is a biotechnology company that develops products based on nanoparticle delivery platform which helps to detect and treat cancer. The company is headquartered in Middlesex, New Jersey, the US.

For a complete picture of Pasifolate exatecan’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.